The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

In 2022, chronic lower respiratory disease was the sixth highest cause of death in the U.S., according to results published ...

Statistics on the representation of women in the CAF as of December 2024 A summary of women's representation rates for officers and non-commissioned members (NCMs) in the Regular Force and Primary ...

Rise in prevalence of cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD) across the globe is the major factor driving the airway clearance market growth. The growth of the market ...

The transcription factor regulatory network in Pseudomonas aeruginosa is complex and involves multiple regulators that respond to various environmental signals and physiological cues by regulating ...

Sensitivity is the likelihood of correctly determining the presence of disease in the whole population that has the disease (true positive rate) whereas specificity is the likelihood of correctly ...

This little Jewish boy’s story shows there is hope for cystic fibrosis sufferers A breakthrough for some who suffer with the inherited condition that causes sticky mucus to build up in the lungs ...

This national representative study suggested a 0.32% to 5.96% prevalence of advanced liver fibrosis risk in the US general population by using non-invasive liver fibrosis scores. Overall, from 39,156 ...

Aug-66 60.2 84.2 36.6 Sep-66 60.2 84.2 36.6 Oct-66 60.2 84.0 36.8 Nov-66 60.2 84.0 36.8 Dec-66 60.2 84.0 36.8 Jan-67 60.2 83.9 37.0 Feb-67 60.2 83.9 37.0 Mar-67 60.2 ...

Elexacaftor-tezacaftor-ivacaftor (ETI) has significantly improved the clinical course of people with cystic fibrosis (pwCF) and eligible CFTR variants. In this study, we prospectively evaluated liver ...